|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum ( 11 ) and cis- diammine-bisursodeoxycholate-platinum ( 11 ) toward liver cells 显示文摘 | Briz O Serrano MA Rebollo N | 2002 | Mol Pharmacol2002，61，4： | 1 |
| 2 | Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma显示文摘 | Rebollo N Calvo MV Martin SA | 2011 | Clin Biochem2011，44，2： | 1 |
| 3 | Way back for fructose and liver metabolism:Bench side to molecular insights显示文摘The World Health Organization recommends that the daily intake of added sugars should make up no more than 10% of total energy.The consumption of sugarsweetened beverages is the main source of added sugars.Fructose,together with glucose,as a component of high fructose corn syrups or as a component of the sucrose molecule,is one of the main sweeteners present in this kind of beverages.Data from prospective and intervention studies clearly point to high fructose consumption,mainly in the form of sweetened beverages,as a risk factor for several metabolic diseases in humans.The incidence of hypertension,nonalcoholic fatty liver disease(NAFLD),dyslipidemia(mainly hypertriglyceridemia),insulin resistance,type 2 diabetes mellitus,obesity,and the cluster of many of these pathologies in the form of metabolic syndrome is higher in human population segments that show high intake of fructose.Adolescent and young adults from lowincome families are especially at risk.We recently reviewed evidence from experimental animals and human data that confirms the deleterious effect of fructose on lipid and glucose metabolism.In this present review we update the information generated in the past 2 years about high consumption of fructose-enriched beverages and the occurrence of metabolic disturbances,especially NAFLD,type 2 diabetes mellitus,and metabolic syndrome.We have explored recent data from observational and experimental human studies,as well as experimental data from animal and cell models.Finally,using information generated in our laboratory and others,we provide a view of the molecular mechanisms that may be specifically involved in the development of liver lipid and glucose metabolic alterations after fructose consumption in liquid form. | Alba Rebollo Núria Roglans Marta Alegret Juan C Laguna | 2012 | World Journal of Gastroenterology2012，18，45： | 1 |
| 4 | Angiotensin Receptor Blocker as Adjunctive Therapy for Rhythm Control in Atrial Fibrillation: Results of the Irbesartan-Amiodarone Trial显示文摘 | Antonio H. Madrid Carlos Escobar José María G. Rebollo Irene Marín Enrique Bernal Sebastián Nannini Lilianna Limón Jian Peng Concepción Moro | 2003 | Cardiac Electrophysiology Review2003，，3： | 1 |
| 5 | Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum (Ⅱ) and cis-diammine-bisursodeoxycholate-platinum (Ⅱ) toward liver cells显示文摘 | BRIZ O SERRANO MA REBOLLO N | 2002 | Mol Pharmacol2002，61，4： | 1 |
| 6 | Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma 显示文摘 | Rebollo N | 2011 | Clin Biochem2011，44，23： | 1 |
| 7 | Angiotensin Receptor Blocker as Adjunctive Therapy for Rhythm Control in Atrial Fibrillation: Results of the Irbesartan-Amiodarone Trial显示文摘 | Antonio H. Madrid Carlos Escobar José María G. Rebollo Irene Marín Enrique Bernal Sebastián Nannini Lilianna Limón Jian Peng Concepción Moro | 2003 | Cardiac Electrophysiology Review2003，，3： | 1 |
| 8 | Angiotensin Receptor Blocker as Adjunctive Therapy for Rhythm Control in Atrial Fibrillation: Results of the Irbesartan-Amiodarone Trial显示文摘 | Antonio H. Madrid Carlos Escobar José María G. Rebollo Irene Marín Enrique Bernal Sebastián Nannini Lilianna Limón Jian Peng Concepción Moro | 2003 | Cardiac Electrophysiology Review2003，，3： | 1 |
| 9 | Relation-ship between speckle correlation and refraction index varia-tion:applications for roughness measurements显示文摘 | Hogert E N Landau M R | 1996 | Optical Engineering1996，35，04： | 1 |
| 10 | Phase stability of Yb Gd codoped zircania 显示文摘 | Rebollo R N Fabrichnaya O Levi C G | 2003 | Acta Mater2003，94，： | 1 |
| 11 | Optical methods for on line surface wire testing显示文摘 | QUINTIAN F P REBOLLO M A GAGGIOLI N G | 1998 | in Proceedings of the 7th European Conference on Non Destructive Testing Broendby Denmark1998，3，8： | 1 |
| 12 | Optimized Orthogonal Matching Pursuit Ap- preach 显示文摘 | Rebollo N L Lowe D | 2002 | Signal Processing Letters IEEE2002，9，4： | 1 |
| 13 | Liquid Fructose Downregulates Liver Insulin Receptor Substrate 2 and Gluconeogenic Enzymes By Modifying Nutrient Sensing Factors In Rats显示文摘 | Alba Rebollo Núria Roglans Miguel Baena Anna Padrosa Rosa M. Sánchez Manuel Merlos Marta Alegret Juan C. Laguna | 2013 | The Journal of Nutritional Biochemistry2013，，： | 1 |
| 14 | Angiotensin receptor blockar as adjunctive therapy for rhythm control in atrial fibrillation results of the irbesartan-amiodarone trial显示文摘 | Lira o n L Rebollo JM Madrid AH | 2003 | Cardiac Electrophysiol Rev2003，7，： | 1 |
| 15 | Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinate-platinum (Ⅱ) and cis-diammine-bisursodeoxycholateplatinum (Ⅱ) toward liver cells显示文摘 | BRIZ O SERRANO M A REBOLLO N | 2002 | Mol Pharmacol2002，61，4： | 1 |
| 16 | Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2) 显示文摘 | BRIZ O SERRANO MA REBOLLO N | 1999 | J Controlled Release1999，57，2： | 1 |
| 17 | Phase stability of Y+Gd co-doped zirconia显示文摘 | Rebollo N R Fabrichnay O Levi C G | 2003 | Zeitschrift Fur Metallkunde2003，94，3： | 1 |
| 18 | Millime- terlong carbon nanotubes: outstanding electron-emitting sources显示文摘 | PEREA L N REBOLLO P B BRIONES L J | 2011 | ACS Nano2011，25，6： | 1 |
| 19 | 埋藏式心脏转复除颤器治疗患者的心房颤动回顾性分析显示文摘回顾性分析埋藏式心脏转复除颤器(ICD)治疗患者中心房颤动(AF)的发生率,评价AF对ICD治疗患者再次住院、不适当放电治疗和总死亡率的影响。182例ICD置入患者,随访48±17个月,用存活率回归分析等相关统计方法,对AF组和窦律(SR)组再住院率、不适当放电治疗和总死亡率等进行比较。结果:两组在室性心律失常再发生率和再住院率上无明显差异(P>0.05)。存活率分析,AF组患者较SR组患者低(P=0.038)。ICD治疗患者,新的AF发生率为8.43%。在AF组中,ICD治疗前有AF病史的患者其不适当放电治疗发生率为25%,而新出现AF病史的患者,不适当放电治疗发生率为64.3%(P<0.05)。结论:ICD治疗后,新发现的AF患者有更高的不适当放电治疗危险。有AF病史的患者,3年存活率比一直为窦性节律的患者低。 | 彭健 José M González Rebollo AntonioHMadrid 易绍东 孟素荣 Concepción Moro | 2005 | 中国心脏起搏与心电生理杂志2005，19，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员